Finally, we applied a novel compound targeting NIK to selectively inhibit the non-canonical NF-κB pathway and showed that venetoclax-resistant CLL cells were sensitized to venetoclax. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.